Experts discuss emerging therapies shaping the future of relapsed and refractory multiple myeloma

In a recent opinion segment, Dr. Ajay Nooka and Dr. Noopur Raje explore how new treatments and ongoing trials are influencing the landscape for patients with relapsed and refractory multiple myeloma.

The conversation highlights a rapid evolution of therapeutic options, including novel agents and cellular approaches, that are moving from early-stage studies toward broader clinical use.

Both physicians stress the importance of integrating emerging data with real-world experience to guide treatment selection, sequencing, and patient referral to advanced therapies.

The segment is part of a larger educational series that addresses multiple aspects of multiple myeloma care, from risk stratification to access barriers and coordinated care across practice settings.